Development of a Glycoconjugate Vaccine to Prevent Meningitis in Africa Caused by Meningococcal Serogroup X

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.1314476110
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Impact of Serogroup a Meningococcal Conjugate Vaccine for Africa

Human Vaccines and Immunotherapeutics
MedicineAllergyImmunologyPharmacology
2018English

Adoption of Serogroup B Meningococcal Vaccine Recommendations

Pediatrics
Child HealthPediatricsPerinatology
2018English

The Course of Generalized Meningococcal Infection Caused by Meningococcus Serogroup W135

CHILDREN INFECTIONS
2016English

Two Cases of Meningococcal Sepsis Caused by Neisseria Meningitidis Serogroup B

Journal of Clinical and Analytical Medicine
Medicine
2016English

Impaired Antibody Response to Conjugated Meningococcal Serogroup C Vaccine in Asplenic Patients

European Journal of Clinical Microbiology and Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2010English

Epidemiology and Prevention of Bacterial Meningitis and Meningococcal Serogroup B Infection

Cocuk Enfeksiyon Dergisi
Child HealthInfectious DiseasesPediatricsPerinatology
2014English

Timely Detection of Meningococcal Meningitis Epidemics in Africa

The Lancet
Medicine
2001English

Potential Benefits of Using a Multicomponent Vaccine for Prevention of Serogroup B Meningococcal Disease

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2019English

Meningococcal Serogroup B Vaccine Immunogenicity in High-Risk Groups: What Are the Implications?

Pediatrics
Child HealthPediatricsPerinatology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy